Clinical trials: Glioma Tumor Recurrence
DIPG, Brain Tumor, Pediatric, Recurrent
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require further treatment.
- Conditions
- DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity
- Trial name
- NCT04670016
- Testing
- This study does not include an intervention.
- Where
- 13 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Glioblastoma Multiforme, GBM
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred…
- Conditions
- Glioblastoma Multiforme, GBM, Gliosarcoma
- Trial name
- NCT01124539
- Testing
- AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
- Where
- 9 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Arno Therapeutics
Recurrent Glioblastoma
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and inhibit tumor cell growth.
- Trial name
- NCT04004975
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shandong Cancer Hospital and Institute
Brain and Central Nervous System Tumors
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or…
- Trial name
- NCT01158300
- Testing
- VEGF inhibitor PTC299
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Brain Neoplasms
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
This is a clinical research study of a new investigational treatment for cancer called "DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is injected directly into the tumor.
- Trial name
- NCT00038441
- Testing
- DTI-015
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG)
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors (low-grade astrocytomas) in children and adults.
- Conditions
- neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
- Trial name
- NCT01338857
- Testing
- Sorafenib (Nexavar)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Astrocytoma, Glioblastoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for…
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Trial name
- NCT07560865
- Testing
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Glioblastoma
Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence
This investigator-initiated, multicenter clinical trial will evaluate the safety and preliminary effectiveness of adding entacapone to bevacizumab in adults with isocitrate dehydrogenase (IDH)-wildtype glioblastoma at first…
- Trial name
- NCT07831187
- Testing
- Entacapone, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Brain and Central Nervous System Tumors
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent…
- Trial name
- NCT00003467
- Testing
- carmustine, polifeprosan 20 with carmustine implant, surgical procedure
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Duke University
Glioma, Recurrent Malignant Glioma
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects.
- Trial name
- NCT02658279
- Testing
- Pembrolizumab
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
Glioblastoma Multiforme
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.
- Trial name
- NCT00730262
- Testing
- TLN-4601
- Where
- 8 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Thallion Pharmaceuticals
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors.
- Conditions
- Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma
- Trial name
- NCT00077454
- Testing
- erlotinib hydrochloride, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Neoplasm, Pineoblastoma
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central…
- Conditions
- Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
- Trial name
- NCT01217437
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 158 sites in United States, Australia and 3 more
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with leucovorin and fluorouracil in treating young patients with advanced solid tumors.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00281944
- Testing
- oxaliplatin, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.